Global provider of cardiac safety, central imaging and endpoint adjudication services for clinical trials, Cardiabase — a Banook Group company, is supporting the World Health Organization (WHO) in the fight against malaria.
Malaria
Cardiabase will provide the WHO with relevant and up-to-date information on the cardiotoxicity of antimalarial drugs when evaluating new malaria treatments in development. Additionally, it will provide crucial information for malaria management recommendations that the WHO publishes on a regular basis.
The company has been working on the review of antimalarial cardiotoxicity for a number of major pharmaceutical and non-profit organisations since 2004. It was also part of the expert group at the Evidence Review Group (ERG) meeting in October 2016 that advised the WHO about antimalarial cardiotoxicity figures.
“Significant progress has been made against malaria over the past decades. We are proud to take part in this battle and to support the WHO and many other organisations in the eradication of one of the oldest infectious diseases known to mankind,” said Pascal Voiriot, chairman of the Banook Group. “Cardiabase is committed to becoming even more responsive to the needs of the developing world and to taking part in initiatives that can lead to better surveillance strategies as well as more efficient and effective treatment.”
Antimalarial drugs, which are vital for treatment, prevention, control and elimination, are structurally related or derived from Quinoline, which is associated with cardiovascular side effects. Therefore, regular cardiotoxicity evaluations of these antimalarial drugs are important for their continued safe use.